Lothar Kanz

Active 1987–2022

149
Papers
28,116
Citations
107
h-index
149
i10-index

Citations

Citations per year for Lothar Kanz1979: 4 citations1987: 1 citations1988: 5 citations1989: 6 citations1990: 4 citations1991: 2 citations1992: 4 citations1993: 7 citations1994: 23 citations1995: 31 citations1996: 35 citations1997: 44 citations1998: 36 citations1999: 61 citations2000: 129 citations2001: 194 citations2002: 223 citations2003: 242 citations2004: 270 citations2005: 256 citations2006: 216 citations2007: 179 citations2008: 205 citations2009: 165 citations2010: 206 citations2011: 205 citations2012: 222 citations2013: 214 citations2014: 187 citations2015: 202 citations2016: 165 citations2017: 185 citations2018: 149 citations2019: 514 citations2020: 614 citations2021: 602 citations2022: 408 citations2023: 299 citations2024: 370 citations2025: 150 citations2026: 2 citations1980–1986: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,437 citing papers, 24.6% of this breakdownGermany: 1,305 citing papers, 13.2% of this breakdownUnited Kingdom: 602 citing papers, 6.1% of this breakdownItaly: 561 citing papers, 5.7% of this breakdownFrance: 488 citing papers, 4.9% of this breakdownChina: 480 citing papers, 4.9% of this breakdownNetherlands: 342 citing papers, 3.5% of this breakdownCanada: 315 citing papers, 3.2% of this breakdownSwitzerland: 291 citing papers, 2.9% of this breakdownSpain: 282 citing papers, 2.9% of this breakdownJapan: 270 citing papers, 2.7% of this breakdownAustralia: 251 citing papers, 2.5% of this breakdown
0%24.6%Other 22.9%

Fields

  • Medicine67.5%
  • Immunology and Microbiology17.7%
  • Biochemistry, Genetics and Molecular Biology12.3%
  • Neuroscience1%
  • Engineering0.4%
  • Materials Science0.3%
  • Other0.8%

Topics

  • Immunotherapy and Immune Responses4.6%
  • Immune Cell Function and Interaction4.6%
  • CAR-T cell therapy research3.9%
  • Lymphoma Diagnosis and Treatment3.8%
  • Acute Myeloid Leukemia Research3.7%
  • Hematopoietic Stem Cell Transplantation3.3%
  • Other76.1%

Coauthors

All papers

Open in search
  1. Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature 2019 cited by 393

  2. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2016 cited by 421

  3. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Christiane Falge, Lothar Kanz, Stephan Kremers, Andreas Burchert, Michael Kneba, Frank Stegelmann, Claus-Henning Köhne, H. W. Lindemann, Cornelius F. Waller, M. Pfreundschuh, Karsten Spiekermann, Wolfgang E. Berdel, Lothar Müller, Matthias Edinger, Jiřı́ Mayer, Dietrich W. Beelen, Martin Bentz, Hartmut Link, Bernd Hertenstein, Roland J. Fuchs, Martin Wernli, Frank Schlegel, Rudolf Schlag, Maike de Wit, Lorenz Trümper, Holger Hebart, Markus Hahn, Jörg Thomalla, Christof Scheid, Philippe Schafhausen, Walter Verbeek, Michael J. Eckart, W. Gaßmann, Antonio Pezzutto, Michael Schenk, Peter Brossart, Thomas Geer, Stephan Bildat, E. Schäfer, Andreas Hochhaus, Joerg Hasford - Leukemia 2017 cited by 339

  4. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial

    Authors: , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2010 cited by 622

  5. Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Haematologica 2020 cited by 121

  6. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia

    Authors: , , , , , , - Blood 2003 cited by 532

  7. Intradermal Vaccinations With RNA Coding for TAA Generate CD8+ and CD4+ Immune Responses and Induce Clinical Benefit in Vaccinated Patients

    Authors: , , , , , , , , , , , , , , - Molecular Therapy 2010 cited by 219

  8. Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2016 cited by 362

  9. Human Signal-Regulatory Protein Is Expressed on Normal, But Not on Subsets of Leukemic Myeloid Cells and Mediates Cellular Adhesion Involving Its Counterreceptor CD47

    Authors: , , , , , , , , - Blood 1999 cited by 294

  10. Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial

    Authors: , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2019 cited by 143

  11. High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 cited by 56

  12. Topotecan – A Novel Topoisomerase I Inhibitor: Pharmacology and Clinical Experience

    Authors: , , , , - Oncology 1999 cited by 215

  13. The Chemokine Receptor CXCR-4 Is Expressed on CD34+Hematopoietic Progenitors and Leukemic Cells and Mediates Transendothelial Migration Induced by Stromal Cell-Derived Factor-1

    Authors: , , , , , - Blood 1998 cited by 635

  14. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Volker Diehl - The Lancet 2012 cited by 632

  15. Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Haematologica 2017 cited by 128

  16. Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Biology of Blood and Marrow Transplantation 2019 cited by 98

  17. Novel Markers for the Prospective Isolation of Human MSC

    Authors: , , , , , - Annals of the New York Academy of Sciences 2007 cited by 453

  18. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Leukemia 2015 cited by 274

  19. Retrospective single center analysis of outcome, risk factors and therapy in steroid refractory graft-versus-host disease after allogeneic hematopoietic cell transplantation

    Authors: , , , , , , , , , , , - Bone Marrow Transplantation 2019 cited by 109

  20. Infusion of cytomegalovirus (CMV)–specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy

    Authors: , , , , , , , , , , , , , - Blood 2002 cited by 701

  21. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Wolfgang Hiddemann, Elizabeth Macintyre, Marie‐Hélène Delfau‐Larue, Christiane Pott, Wolfgang Hiddemann, Michael Unterhalt, Martin Dreyling - The Lancet 2016 cited by 401

  22. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Rüdiger Hehlmann, for the Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK) and the German CML Study Group - Blood 2011 cited by 290

  23. SOX2 Expression Associates with Stem Cell State in Human Ovarian Carcinoma

    Authors: , , , , , , , , , , , , , , , , , , - Cancer Research 2013 cited by 152

  24. Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Haematologica 2014 cited by 119